Лечение анемии в онкологии: роль нового стимулятора эритропоэза Аранесп (дарбэпоэтин альфа)

1. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tri-part assessment survey, The Fatigue Coalition. Semin Hematol. 1997;34 (3 suppl 2):4-12. 
2. Kurt GA, Breitbart W, Cella DF, et al. Impact of cancer-related fatigue on the lives of patients. Proc Am Soc Clin Oncol. 1999;18:573A. 
3. Ashbury FD et al. A Canadian survey of cancer patients' experiences: are their needs being met? J Pain Symptom Manage 1998; 16: 298–306.  
4. Cella  D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997; 34(3 Suppl 2):13-9.
5. Lefebvre P, Vecerman F., Sarokham B. et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin Cur Med Res Opin 2006; 22:1929-37 
6. Ludwig H, Van Bells S, Barret-Lee P, et al The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40:2293-306
7. Teicher BA, Abrams MJ, Rosbe KW, et al. Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex. Cancer Res. 1990; 50:6971-5
8. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285-9 
9. Bunn, H. F., and R. O. Poyton. Activation of the HIF pathway in cancer. Curr Oppin Gen Dev 2001;11:293-9 
10. Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998; 17: 303–311
11. Graeber T.G., Osmanian C.Jacks T., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996 Jan 4;379(6560):88-91 
12. Caro JJ, Salas M, Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.Cancer. 2001;91:2214-21
13. DeRienzo DP, Saleem A. Anemia of chronic disease: a review of pathogenesis Tex Med 1990;86:80-3
14. Moldawer LL, Marano MA, Wei H et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo.FASEB J. 1989;3:1637-43 
15. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3 
16. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer.N Engl J Med. 1990 ;322:1689-92 
17. Blajchman MA, Vamvakas EC,  The Continuing Risk of Transfusion-Transmitted Infections NEJM 2006, 355, 1303-1305
18. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997;336:933– Bolhius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-14. Review 
19. Bolhius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-14. Review
20. Miyake T, Kung CK and Goldwasser E (1977) Purification of human erythropoietin J Biol Chem 252: 5558–5564
21. Lai PH, Everett R, Wang FF, Arakawa T and Goldwasser E (1986) Structural characterization of human erythropoietin. J Biol Chem 261: 3116–3121
22. Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland T, Watson E and Stebbing N (1986) Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 51: 693–702 
23. Sasaki H, Bothner B, Dell A and Fukuda M (1987) Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262: 12059–12076
24. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA and Wiley DC (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 81: 1779–1783
25. Fukuda MN, Sasaki H, Lopez L and Fukuda M (1989) Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73: 84–89
26. Dordal MS, Wang FF and Goldwasser E (1985) The role of carbohydrate in erythropoietin action. Endocrinology 116: 2293–2299
27. Lin FK (1987) The molecular biology of erythropoietin. In: Rich IN, (ed) Molecular and cellular aspects of erythropoietin and erythropoiesis. pp. 23–36.  New York: Springer
28. Elliott SG, Lorenzini T, Strickland T, Delorme E and Egrie JC (2000) Rational design of novel erythropoiesis stimulating protein (ARANESP™): a super-sialated molecule with increased biological activity. Blood 96: 82a (abstract 352)
29. Egrie JC, Dwyer E, Lykos M, Hitz A and Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO).  Blood 90: 56a (abstract 243)
30. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211–20
31. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131–8.
32. Vadhan-Raj S, Mirtsching B, Gregory SA, et al. Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks  (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA) [abstract]. Proc Am Soc Clin Oncol 2004;23:740.
33. Thames WA, Smith SL, Schiefele AC, Yao B, Giffin SA, Alley JL. Evaluation of the US Oncology Network’s recommended guidelines for therapeutic substitution with darbepoetin alfa 200 µg every 2 weeks in both naХve patients and patients switched from epoetin alfa. Pharmacotherapy 2004;24: 313–23.
34. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study to compare the utilization patterns and clinical outcomes of erythropoietic proteins for chemotherapy-induced anemia. Clin Ther 2003;25:2781–96.
35. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 µg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642–50.
36. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 study group trial. J Clin Oncol 2006;24:2290–7.
37. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: results of a doubleblind,  placebo-controlled, randomised study. Eur J Cancer 2003;39:2026–34.
38. Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every 3 weeks is effective for the treatment of chemotherapyinduced anemia. Oncologist 2006;11:409–17.
39. Canon J-L, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273–84.
40. Gotlib J, Quesada S, Bhamidipati J, et al. Phase II trial of darbepoetin alfa in myelodysplastic syndrome (MDS):  preliminary efficacy, safety, and in vitro results [abstract]. Blood 2004;104:abstract 4737.
41. Gabrilove J, Paquette R, Lyons R, et al. A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome [abstract]. Blood 2005;106:abstract 2541.